A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 30 Jul 2014
Price : $35 *
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.